

# EVERCORE

Board of Directors  
Takeda Pharmaceutical Company Limited  
1-1, Doshomachi 4-chome  
Chuo-ku  
Osaka 540-8645  
Japan

8 May 2018

Dear Sirs

## **Recommended offer by Takeda Pharmaceutical Company Limited (“Takeda”) for Shire plc (“Shire”) (the “Acquisition”)**

We refer to the announcement by Takeda to be issued under Rule 2.7 of the City Code on Takeovers and Mergers (the “**Code**”) on or around 8 May 2018 in connection with the Acquisition, a copy of which is attached hereto (the “**Announcement**”).

The Announcement includes certain references to Evercore Partners International LLP (“**Evercore**”).

We hereby confirm that Evercore has given and not withdrawn its consent to the inclusion in the Announcement of references to its name, in the form and context in which they appear. This letter is for your information only and should not be relied upon by any other person.

Evercore’s consent is required by Rule 23.2 of the Code and is given solely for the purpose of complying with that provision and for no other purpose.

Yours faithfully

/s/ Julian Oakley  
Julian Oakley  
Senior Managing Director

For and on behalf of  
Evercore Partners International LLP